Research programme: anti-hepatitis C virus human monoclonal antibodies - XTL Biopharmaceuticals

Drug Profile

Research programme: anti-hepatitis C virus human monoclonal antibodies - XTL Biopharmaceuticals

Alternative Names: CBH-2; CBH-5; XTL-003

Latest Information Update: 05 Mar 2007

Price : $50

At a glance

  • Originator XTL Biopharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 05 Mar 2007 Discontinued - Preclinical for Hepatitis C in Israel (unspecified route)
  • 26 Apr 2001 Preclinical development for Hepatitis C in Israel (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top